NCT06186076View on ClinicalTrials.gov

A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

June 14, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
Carcinoma, Non-Small-Cell LungEGFR Mutant Advanced Non-Small Cell Lung Cancer
Interventions
DRUG

TRX-221

TRX-221 oral dose as defined

Trial Locations (6)

13620

ACTIVE_NOT_RECRUITING

Seoul National University Bundang Hospital, Seongnam

16247

ACTIVE_NOT_RECRUITING

The Catholic University of Korea St. Vincent Hospital, Suwon

28644

RECRUITING

Chungbuk National University Hospital, Chungju

03722

RECRUITING

Severance Hospital, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Therapex Co., Ltd

INDUSTRY